Jci_page_head_homepage_01 Jci_page_head_homepage_02
Dan Yang, Ying Zhang, Hao G. Nguyen, Milka Koupenova, Anil K. Chauhan, Maria Makitalo, Matthew R. Jones, Cynthia St. Hilaire, David C. Seldin, Paul Toselli, Edward Lamperti, Barbara M. Schreiber, Haralambos Gavras, Denisa D. Wagner, Katya Ravid
Published in Volume 116, Issue 7
J Clin Invest. 2006; 116(7):1913–1923 doi:10.1172/JCI27933
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Generation of A2B AR-KO mice.

(A) Scheme of the A2BAR gene (top), the targeting vector (middle), and the resulting A2BAR-KO/β-gal–knock-in gene (bottom). On the latter, the restrictions sites (ApaL1) used to digest genomic DNA for Southern blot analysis of tail genomic DNA (B) are indicated, as well as the sites for sense (s) and antisense (as) primers used for PCR analysis of tail genomic DNA (C). The expected products for the WT (+/+) and KO (–/–) mice are indicated. (D) A2BAR mRNA in different tissues. RNA was prepared from different tissues derived from WT or KO mice and subjected to RT-PCR to amplify exon 1 as described in Methods. (E) A2BAR activation in primary aortic VSMCs. cAMP was measured in cells derived from WT or KO mice after treatment with vehicle, 5 μM NECA, or 5 μM forskolin in the presence or absence of 5 μM of the A2BAR antagonist MRS1754 as indicated. Data are presented as average ± SD for 3 experiments performed in duplicate.